

PRESS RELEASE

November 5, 2007
ONCOLYS BIOPHARMA INC.

Oncolys BioPharma Opens New Research Center in Kobe

Tokyo, Japan - November 5, 2007 - Oncolys BioPharma Inc. (Tokyo, Japan, President & CEO, Yasuo Urata), opens new research center in Kobe on November 6.

Oncolys BioPharma Inc. has researched for the production oncolytic adenoviruses such as Teromelysin® and TelomeScan®, and checked up quality control in Kyoto Research Center since 2006. We aim at the production of a virus in high quality with well-equipment in our new Kobe research center.

“The Main purpose of opening this research center is the production of TelomeScan®, for in vitro cancer diagnosis, in high quality more. I hope that collaboration with Sysmex Corporation will advance our research more, and then this research center will become the basis for Good Manufacturing Practice (GMP) samples in future.” said Yasuo Urata, President and CEO of the company.

Kobe Research Center of Oncolys BioPharma Inc.
Business Support Center for Biomedical Research Activities
1-5-5 Minatojimaminamimachi, Chuo-ku, Kobe 650-0047, Japan

Area : 204 m²

Mission : Manufacturing and Quality Control of adenoviruses such as
Teromelysin® and TelomeScan®

About Oncolys BioPharma, Inc.

Oncolys BioPharma is a private held biopharmaceutical company focused on the development of novel biologics for the treatment of cancer and infectious disease. The company's leading product for the treatment of cancer, Telomelysin® (OBP-301), is based on replication-competent oncolytic virus, and is being tested on Phase-I clinical trial in the U.S. for various solid tumors. A novel cancer diagnostic product, Telomescan® (OBP-401), is on validation stage (feasibility

studies) and is expected to be effective in detecting most types of cancer. The company also has another major pipeline for infectious disease, OBP-601, on late pre-clinical stage (Pre-IND) for HIV/AIDS therapy. OBP-601 is a novel NRTI with highly promising safety and resistance profiles. For additional information, please visit www.oncolys.com.

CONTACT:

ONCOLYS BIOPHARMA, INC.

3-16-33 Roppongi, Minato-ku, Tokyo 106-0032, Japan

Tel : +81-3-5575-3378 Fax: +81-3-5575-0488

anticancer@oncolys.com